Dreampath obtains first US patent for its block management archiving solution.

Dreampath Diagnostics is the Global Leader in automation of traceability of patient samples in pathology.

Dreampath is based in Strasbourg, France and produces all their products, including the consumables, in the Rhyne Valley Region in Europe. Their products are of highest quality and comply with all international standards for quality, robustness and safety.

Dreampath leadership, innovation and technology lies on automation of traceability of samples in pathology laboratories.

Dreampath has just obtained its first US patent. Mrs Wilhelm, Head of R&D and Operation said : “This is great news for our team as a recognition from the intellectual property authorities about our capacity to innovate.”

Dreampath invests heavily on R&D to bring innovative solutions in pathology. We invest as well heavily on our IP strategy and defending our patents.

Pablo Jordan, Dreampath’s CEO said “this first US patent is a pillar of our USA commercialization strategy. Thanks to the wide claims of our US patent we can now fully concentrate on continue our solid commercialization in the USA.”

Indeed, several key claims on automation of traceability are covered under this patent.

“The US market represents for us a key focus and with this patent we reinforce our strong position”, says Pablo Jordan.